Trials / Terminated
TerminatedNCT00430742
An Investigational Drug Study to Assess Weight Loss in Patients With Type 2 Diabetes Mellitus (0364-011)(TERMINATED)
A Phase III Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of Taranabant (MK0364) in Overweight and Obese Patients With Type 2 Diabetes Mellitus (T2DM) Followed by a 1-Year Extension
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 600 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
A worldwide study with extension in patients with type 2 diabetes mellitus to assess the safety and tolerability as well as the effects of treatment with an investigational drug for weight loss on body weight.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Taranabant | Taranabant 0.5 mg, 1 mg capsule, 2 mg capsule once daily Treatment for 52 weeks. |
| DRUG | Comparator: Placebo | Placebo capsule once daily. Treatment for 52 weeks. |
Timeline
- Start date
- 2006-11-01
- Primary completion
- 2008-01-01
- Completion
- 2008-11-01
- First posted
- 2007-02-02
- Last updated
- 2015-02-13
Source: ClinicalTrials.gov record NCT00430742. Inclusion in this directory is not an endorsement.